Welcome Daniel Dormont Senior Consultant and General Counsel
Brinks DEA Consulting is excited to announce that Daniel Dormont has joined the firm as Senior Consultant and General Counsel. Mr. Dormont is one of the nation’s leading experts on the regulation of controlled substances, having served for more than 30 years as an attorney in the U.S. Department of Justice, Drug Enforcement Administration (DEA), and in the U.S. Food and Drug Administration (FDA). Among the key positions Mr. Dormont held while at DEA was the Chief of the section of attorneys responsible for reviewing all regulatory matters arising out of the agency’s Diversion Control Division, as well as the agency’s Legislative Counsel.
During his career with the Drug Enforcement Administration (DEA), Mr. Daniel Dormont advised DEA Administrators, United States Attorneys General, United States Attorneys, and other senior officials within DEA and the Department of Justice on a wide array of criminal, civil, and administrative provisions pertaining to controlled substances. He wrote numerous provisions of the Controlled Substances Act, DEA regulations, and agency policy documents on topics such as the following:
- Telemedicine – Prescribing and dispensing of controlled substances by means of the Internet (the Ryan Haight Act)
- Immediate suspension orders served on DEA registrants
- Corrective action plans for registrants facing revocation of registration
- Legitimate medical purpose requirement for prescriptions issued by practitioners and the corresponding responsibility of pharmacists
- Dispensing of controlled substances for the treatment of pain
- Dispensing of controlled substances at long-term care facilities
- Dispensing of controlled substances by veterinarians in multiple states
- Delivery of controlled substances by a pharmacy to the prescribing practitioner
- Addiction treatment – Administering controlled substances by narcotic treatment programs and hospitals
- Imports and exports of controlled substances
- Emergency medical services – registration and handling of controlled substances
- Research – Applications for schedule I DEA registration
- Electronic prescriptions for controlled substances
- Disposal of controlled substances
- Issuance by practitioners of multiple schedule II prescriptions
- Scheduling and regulation of anabolic steroids
- Advertising the sale of controlled substances over the Internet
- DEA Quotas
- DEA Scheduling Actions
- Controls To Enhance the Cultivation of Marijuana for Research in the United States
As an Associate Chief Counsel at the DEA, Mr. Dormont supervised the team of attorneys responsible for reviewing all regulatory matters arising out of the agency’s Diversion Control Division. He also briefed and argued cases on behalf of the Department of Justice before the United States Court of Appeals. As an Associate Chief Counsel at the U.S. Food and Drug Administration, Mr. Daniel Dormont’s areas of focus included: shortages of controlled substances and related DEA quota considerations; scheduling of controlled substances; Drug Supply Chain Security Act; and Investigational New Drug Applications (INDs).
Mr. Daniel Dormont earned a Bachelor of Arts degree in mathematics from the University of Pennsylvania and a Juris Doctor from Boston College Law School.